The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy

Nature Communications

Volumn 7, Issue , 2016, Pages

  Lukey, Michael J ^a   Greene, Kai Su ^a   Erickson, Jon W ^a   Wilson, Kristin F ^a   Cerione, Richard A ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMINASE; MITOCHONDRIAL ENZYME; PROTEIN C JUN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; GLUTAMINE; PROTEIN BINDING;

CANCER; CELLS AND CELL COMPONENTS; CYTOGENETICS; DISEASE TREATMENT; GENE EXPRESSION; GLUCOSE; INHIBITION; METABOLISM; PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; CELL METABOLISM; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MITOCHONDRION; NUCLEAR REPROGRAMMING; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIZATION; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; CELL PROLIFERATION; CELL TRANSFORMATION; CYTOLOGY; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; MAMMALIAN EMBRYO; MCF-7 CELL LINE; METABOLISM; MOLECULAR GENETICS; MOUSE; NEOPLASMS; NUCLEOTIDE SEQUENCE; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; EMBRYO, MAMMALIAN; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMINASE; GLUTAMINE; HUMANS; MCF-7 CELLS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-JUN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO GTP-BINDING PROTEINS; RNA INTERFERENCE;

EID: 84973333080     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11321     Document Type: Article

References (68)

1. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. & Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11-20 (2008).
2. Dang, C. V. Links between metabolism and cancer. Genes Dev. 26, 877-890 (2012).
3. Lunt, S. Y. & Vander Heiden, M. G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27, 441-464 (2011).
4. Tong, X., Zhao, F. & Thompson, C. B. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr. Opin. Genet. Dev. 19, 32-37 (2009).
5. Lukey, M. J., Wilson, K. F. & Cerione, R. A. Therapeutic strategies impacting cancer cell glutamine metabolism. Future Med. Chem. 5, 1685-1700 (2013).
6. Daye, D. & Wellen, K. E. Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis. Semin. Cell Dev. Biol. 23, 362-369 (2012).
7. DeBerardinis, R. J. & Cheng, T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29, 313-324 (2010).
8. Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95 (2011).
9. Kroemer, G. & Pouyssegur, J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-482 (2008).
10. DeBerardinis, R. J. et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl Acad. Sci. USA 104, 19345-19350 (2007).
11. Le, A. et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in b cells. Cell Metab. 15, 110-121 (2012).
12. de la Rosa, V. et al. A novel glutaminase isoform in mammalian tissues. Neurochem. Int. 55, 76-84 (2009).
13. Hu, W. et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl Acad. Sci. USA 107, 7455-7460 (2010).
14. Cassago, A. et al. Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism. Proc. Natl Acad. Sci. USA 109, 1092-1097 (2012).
15. Mohamed, A., Deng, X., Khuri, F. R. & Owonikoko, T. K. Altered glutamine metabolism and therapeutic opportunities for lung cancer. Clin. Lung Cancer 15, 7-15 (2014).
16. Huang, F., Zhang, Q., Ma, H., Lv, Q. & Zhang, T. Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. Int. J. Clin. Exp. Pathol. 7, 1093-1100 (2014).
17. Pan, T. et al. Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer. Biochem. Biophys. Res. Commun. 456, 452-458 (2015).
18. Szeliga, M. et al. Silencing of GLS and overexpression of GLS2 genes cooperate in decreasing the proliferation and viability of glioblastoma cells. Tumor Biol. 35, 1855-1862 (2014).
19. Robinson, M. M. et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem. J. 406, 407-414 (2007).
20. Wang, J. Bin et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18, 207-219 (2010).
21. Gross, M. I. et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13, 890-901 (2014).
22. Wise, D. R. et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl Acad. Sci. USA 105, 18782-18787 (2008).
23. Gao, P. et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762-765 (2009).
24. Yuneva, M. O. et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 15, 157-170 (2012).
25. Xia, Z. et al. Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3′-UTR landscape across seven tumour types. Nat. Commun. 5, 5274 (2014).
26. Bott, A. J. et al. Oncogenic Myc induces expression of glutamine synthetase through promoter demethylation. Cell Metab. 22, 1068-1077 (2015).
27. Qie, S., Chu, C., Li, W., Wang, C. & Sang, N. ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation. J. Cell. Biochem. 115, 498-509 (2014).
28. Kenny, J. et al. Bacterial expression, purification, and characterization of rat kidney-type mitochondrial glutaminase. Protein Expr. Purif. 31, 140-148 (2003).
29. Angel, P., Hattori, K., Smeal, T. & Karin, M. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 55, 875-885 (1988).
30. Sabapathy, K. et al. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol. Cell 15, 713-725 (2004).
31. Li, Z. et al. Regulation of PTEN by Rho small GTPases. Nat. Cell Biol. 7, 399-404 (2005).
32. Csibi, A. et al. The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation. Curr. Biol. 24, 2274-2280 (2014).
33. Fanjul, A. et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372, 107-111 (1994).
34. Lei, K. et al. The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase. Mol. Cell. Biol. 22, 4929-4942 (2002).
35. Zhao, C. et al. Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer. Cancer Res. 74, 3983-3994 (2014).
36. Vleugel, M. M., Greijer, A. E., Bos, R., van der Wall, E. & van Diest, P. J. c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum. Pathol. 37, 668-674 (2006).
37. Shao, J. et al. COP1 and GSK3β cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis. Neoplasia 15, 1075-1085 (2013).
38. Singh, R. et al. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology 49, 87-96 (2009).
39. Yang, G. et al. Isoform-specific palmitoylation of JNK regulates axonal development. Cell Death Differ. 19, 553-561 (2012).
40. Zhao, L. et al. Interferon-α regulates glutaminase 1 promoter through STAT1 phosphorylation: relevance to HIV-1 associated neurocognitive disorders. PLoS ONE 7, e32995 (2012).
41. Reynolds, M. R. et al. Control of glutamine metabolism by the tumor suppressor Rb. Oncogene 33, 556-566 (2014).
42. Messeguer, X. et al. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 18, 333-334 (2002).
43. Koudritsky, M. & Domany, E. Positional distribution of human transcription factor binding sites. Nucleic Acids Res. 36, 6795-6805 (2008).
44. Yang, W. et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955-D961 (2013).
45. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
46. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1-pl1 (2013).
47. Florin, L. et al. Identification of novel AP-1 target genes in fibroblasts regulated during cutaneous wound healing. Oncogene 23, 7005-7017 (2004).
48. Eferl, R. & Wagner, E. F. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 3, 859-868 (2003).
49. Shaulian, E. & Karin, M. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4, E131-E136 (2002).
50. Cheng, T. et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc. Natl Acad. Sci. USA 108, 8674-8679 (2011).
51. Stalnecker, C. A. et al. Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells. Proc. Natl Acad. Sci. USA 112, 394-399 (2014).
52. Maki, Y., Bos, T. J., Davis, C., Starbuck, M. & Vogt, P. K. Avian sarcoma virus 17 carries the jun oncogene. Proc. Natl Acad. Sci. USA 84, 2848-2852 (1987).
53. Bohmann, D. et al. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 238, 1386-1392 (1987).
54. Schreiber, M. et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 13, 607-619 (1999).
55. Lallemand, D., Spyrou, G., Yaniv, M. & Pfarr, C. M. Variations in Jun and Fos protein expression and AP-1 activity in cycling, resting and stimulated fibroblasts. Oncogene 14, 819-830 (1997).
56. Wada, T. et al. MKK7 couples stress signalling to G2/M cell-cycle progression and cellular senescence. Nat. Cell Biol. 6, 215-226 (2004).
57. Shaulian, E. & Karin, M. AP-1 in cell proliferation and survival. Oncogene 20, 2390-2400 (2001).
58. Goodrich, D. W., Wang, N. P., Qian, Y. W., Lee, E. Y. & Lee, W. H. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67, 293-302 (1991).
59. Mariani, O. et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell 11, 361-374 (2007).
60. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
61. Kappelmann, M., Kuphal, S., Meister, G., Vardimon, L. & Bosserhoff, A.-K. MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. Oncogene 32, 2984-2991 (2013).
62. Bakiri, L., Matsuo, K., Wisniewska, M., Wagner, E. F. & Yaniv, M. Promoter specificity and biological activity of tethered AP-1 dimers. Mol. Cell. Biol. 22, 4952-4964 (2002).
63. Mechta-Grigoriou, F., Gerald, D. & Yaniv, M. The mammalian Jun proteins: redundancy and specificity. Oncogene 20, 2378-2389 (2001).
64. Smith, L. M. et al. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18, 6063-6070 (1999).
65. Liu, Y. et al. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene 23, 8238-8246 (2004).
66. Wang, X. et al. Elevated expression of phosphorylated c-Jun NH2-terminal kinase in basal-like and 'triple-negative' breast cancers. Hum. Pathol. 41, 401-406 (2010).
67. Horiuchi, D. et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J. Exp. Med. 209, 679-696 (2012).
68. Wang, Z.-Y. et al. Regulation of IL-10 gene expression in Th2 cells by Jun proteins. J. Immunol. 174, 2098-2105 (2005).